Atrial Flutter (AFL)

How to Cite This Chapter: Acosta Velez JG, Amit G, Hernández Ruiz EA, Trusz-Gluza M, Leśniak W. Atrial Flutter (AFL). McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. Accessed February 02, 2023.
Last Updated: February 20, 2022
Last Reviewed: February 20, 2022
Chapter Information

Definition, Etiology, PathogenesisTop

Atrial flutter (AFL) is a macroreentrant arrhythmia (spinning around a large circuit in the atrium) characterized by a regular atrial rate (usually 250-300 beats/min) and a constant P wave morphology. Paroxysmal AFL can occur in patients with no apparent structural heart disease, whereas chronic AFL is usually associated with preexisting conditions, such as valvular or ischemic heart disease or cardiomyopathy. Those at the highest risk of developing AFL are men, older adults, and individuals with preexisting heart failure or chronic obstructive pulmonary disease. In ~60% of cases AFL occurs as part of an acute disease process. The same risk factors that increase the risk of atrial fibrillation (AF) also apply to AFL.

In >90% of patients with AFL, the AFL circuit involves the cavotricuspid isthmus (CTI), which is the critical area for sustaining the flutter and where efforts to ablate may be directed. AFL can occur in clinical settings similar to those associated with atrial fibrillation (AF) and may be triggered by atrial tachycardia (AT) or AF. Non–CTI-dependent flutter is called atypical and is commonly seen in patients with previous AF ablation, severe left atrial disease, or previous atrial surgery.

Clinical Features and Natural HistoryTop

AFL is frequently recurrent and attacks are usually accompanied by tachyarrhythmia. Some patients may be asymptomatic in chronic AFL. Antiarrhythmic drugs and heart rate medications are less effective in AFL than in other types of supraventricular arrhythmias and thus a general recommendation is to either combine atrioventricular (AV) nodal blockers if rate control is intended or consider electrical cardioversion.

In individuals with AF treated with class Ic drugs (see Table 3.4-1), there is a small risk of AF organizing into AFL, and this is the reason why flecainide should always be associated with an AV nodal blocker. This is not the case for propafenone.

Clinical signs and symptoms largely depend on the type and severity of the underlying condition and include palpitations (most commonly), dyspnea, weakness, or chest pain. Some patients may be asymptomatic. Heart rates are fast (~150 beats/min) and regular.


Diagnostic Tests

Electrocardiography (ECG): The AFL waves are due to rapidly reoccurring atrial depolarizations without isoelectric baseline between the consecutive waves. This gives the "saw tooth" or "picked fence" pattern to this arrhythmia. Typical AFL (CTI-dependent, counterclockwise rotation around the tricuspid valve) is characterized by dominant negative flutter waves in the inferior leads and a positive P wave in lead V1. Reverse typical AFL (CTI-dependent, counterclockwise rotation around the valve) shows the opposite pattern, with a positive flutter wave in the inferior leads and a negative P wave in lead V1. Carotid sinus massage or adenosine can be useful to transiently increase the degree of the AV block and facilitate diagnosis.

Differential Diagnosis

Supraventricular tachycardia: see Figure 3.4-2. Narrow-QRS tachycardia: see Figure 3.4-3. Wide-QRS tachycardia: see Figure 3.4-4.


Classification of antiarrhythmic drugs: see Table 3.4-1.

Antiarrhythmic agents: see Table 3.4-2.

AFL treatment algorithm: Figure 3.4-9.

Acute Management

1. Electrical cardioversion: AFL does not respond well to drugs in general. Electrical cardioversion should be considered early in the management of patents with AFL. Usually a low-energy (50-100 J) shock is used. Prevention of thromboembolism is used as in AF (see Atrial Fibrillation).

2. Pharmacologic treatment: Figure 3.4-9.

Long-Term Management

Guidelines for drug selection (Figure 3.4-9) are similar to those used in AF, but the effectiveness of antiarrhythmic drugs is significantly inferior to ablation and lower than when used for AF. Rate control may also be difficult to achieve in AFL. In CTI-dependent AFL, catheter ablation has a high success rate with a very low complication rate and may be offered even to patients after a first well-tolerated AFL attack. In atypical AFL, ablation is a more complex procedure with higher recurrence rates and should be considered depending on the patient’s profile.


AFL increases the risk of thromboembolic complications, including ischemic stroke. Therefore, thromboembolism prevention is required, as in patients with AF (see Atrial Fibrillation).


Figure 3.4-9. Treatment of macroreentrant atrial tachycardia. Based on the 2019 European Society of Cardiology guidelines.

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.